GANX – gain therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease [Yahoo! Finance]
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
Hansa Biopharma interim report January-March 2024 [Yahoo! Finance]
Form ARS Gain Therapeutics, Inc. For: Dec 31
Form DEFA14A Gain Therapeutics, Inc.
Form DEF 14A Gain Therapeutics, Inc. For: Jun 24
Form 4 Gain Therapeutics, Inc. For: Apr 08 Filed by: Mack Gene
Form 3 Gain Therapeutics, Inc. For: Apr 05 Filed by: Mack Gene
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.